SCHEMBL10244781

SCHEMBL10244781

CCCCNC(=O)c1ccoc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.58
TSHR P16473 1/20 0.53
HTT P42858 1/20 0.53
NAAA Q02083 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.51
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
ALDH1A1 P00352 3/20 0.47
MLYCD O95822 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 2/20 0.46
PTK2 Q05397 1/20 0.46
CA2 P00918 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
CASP1 P29466 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6360179 0.90 L3MBTL1 (0.50) SMN1; SMN2NAAAL3MBTL1HDAC3HDAC1
SCHEMBL16357638 0.83 HDAC3 (0.57) TSHRHDAC3HDAC1ALDH1A1MEN1
SCHEMBL15924222 0.83 FOLH1 (0.47) SMN1; SMN2NAAAL3MBTL1HDAC3HDAC1
SCHEMBL13617144 0.83 HDAC3 (0.48) SMN1; SMN2TSHRHTTNAAAHDAC3
SCHEMBL14996246 0.83 TRPA1 (0.56) SMN1; SMN2TSHRL3MBTL1HDAC3HDAC1
SCHEMBL3273821 0.82 PTK2 (0.50) HDAC3HDAC1PTK2RAB9A
SCHEMBL28326194 0.80 L3MBTL1 (0.73) SMN1; SMN2TSHRHTTNAAAL3MBTL1
SCHEMBL8638091 0.80 HDAC3 (0.51) NAAAHDAC3HDAC1CA2NPC1
SCHEMBL18912552 0.79 MAOB (0.54) TSHRHDAC3HDAC1PTK2MEN1
SCHEMBL1231519 0.79 HDAC3 (0.57) SMN1; SMN2HTTHDAC3HDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389216-B1 AVERMECTINS SUBSTITUTED IN THE 4\"-POSITION HAVING PESTICIDAL PROPERTIES MERIAL INC (US) 2017-02-22 EP disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-7732416-B2 For protecting plants against parasitic feeding pests; also against the infestation of pets, especially cats and dogs, by fleas, ticks and nematodes; pesticides for crop protection MERIAL LIMITED (US) 2010-06-08 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-7605134-B2 Pesticides MERIAL LIMITED (US) 2009-10-20 US disclosed
US-7605134-B2 Pesticides MERIAL LIMITED (US) 2009-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885TSHR 1567/4885HTT 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.